View Item 

Show simple item record

Janus Family kinase (JAK) inhibitors in HLH and severe COVID‐19
dc.contributor.authorWilcox, Ryan A.
dc.date.accessioned2020-12-02T14:38:09Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-12-02T14:38:09Z
dc.date.issued2020-12
dc.identifier.citationWilcox, Ryan A. (2020). "Janus Family kinase (JAK) inhibitors in HLH and severe COVID‐19." American Journal of Hematology 95(12): 1448-1451.
dc.identifier.issn0361-8609
dc.identifier.issn1096-8652
dc.identifier.urihttps://hdl.handle.net/2027.42/163587
dc.publisherJohn Wiley & Sons, Inc.
dc.titleJanus Family kinase (JAK) inhibitors in HLH and severe COVID‐19
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biology
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.subject.hlbtoplevelScience
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163587/2/ajh25985_am.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163587/1/ajh25985.pdfen_US
dc.identifier.doi10.1002/ajh.25985
dc.identifier.sourceAmerican Journal of Hematology
dc.identifier.citedreferenceJenkins SJ, Ruckerl D, Thomas GD, et al. IL‐4 directly signals tissue‐resident macrophages to proliferate beyond homeostatic levels controlled by CSF‐1. J Exp Mmed. 2013; 210: 2477 ‐ 2491.
dc.identifier.citedreferenceWang T, Feldman AL, Wada DA, et al. GATA‐3 expression identifies a high‐risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014; 123: 3007 ‐ 3015.
dc.identifier.citedreferenceCantini F, Niccoli L, Nannini C, et al. Beneficial impact of Baricitinib in COVID‐19 moderate pneumonia; multicentre study. J Infect. 2020; 81 ( 4 ): 647 ‐ 679.
dc.identifier.citedreferenceCantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID‐19: a pilot study on safety and clinical impact. J Infect. 2020; 81: 318 ‐ 356.
dc.identifier.citedreferenceStebbing J, Phelan A, Griffin I, et al. COVID‐19: combining antiviral and anti‐inflammatory treatments. Lancet Infect Dis. 2020; 20: 400 ‐ 402.
dc.identifier.citedreferenceBekerman E, Neveu G, Shulla A, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad‐spectrum antiviral effects. J Clin Invest. 2017; 127: 1338 ‐ 1352.
dc.identifier.citedreferenceSinger JW, Fleischman A, Al‐Fayoumi S, Mascarenhas JO, Yu Q, Agarwal A. Inhibition of interleukin‐1 receptor‐associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget. 2018; 9: 33416 ‐ 33439.
dc.identifier.citedreferenceKawai T, Akira S. The role of pattern‐recognition receptors in innate immunity: update on Toll‐like receptors. Nat Immunol. 2010; 11: 373 ‐ 384.
dc.identifier.citedreferencePolk A, Lu Y, Wang T, et al. Colony‐stimulating factor‐1 receptor Is required for nurse‐like cell survival in chronic lymphocytic leukemia. Clin Cancer Res. 2016; 22: 6118 ‐ 6128.
dc.identifier.citedreferenceWu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180: 934 ‐ 943.
dc.identifier.citedreferenceGrifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS‐CoV‐2 Coronavirus in Humans with COVID‐19 Disease and Unexposed Individuals. Cell. 2020; 181: 1489 ‐ 1501. e1415.
dc.identifier.citedreferenceWeiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS‐CoV‐2‐specific T cells in COVID‐19 patients with acute respiratory distress syndrome. Sci Immunol. 2020; 5: eabd2071.
dc.identifier.citedreferenceMateus J, Grifoni A, Tarke A, et al. Selective and cross‐reactive SARS‐CoV‐2 T cell epitopes in unexposed humans. Science. 2020;370(6512):89‐94.
dc.identifier.citedreferencePayne DC, Smith‐Jeffcoat SE, Nowak G, et al. SARS‐CoV‐2 infections and serologic responses from a sample of U.S. Navy Service Members ‐ USS Theodore Roosevelt, April 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 714 ‐ 721.
dc.identifier.citedreferenceGandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles’ Heel of current strategies to control Covid‐19. N Engl J med. 2020; 382: 2158 ‐ 2160.
dc.identifier.citedreferenceMizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID‐19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020; 25 ( 10 ): 1 ‐ 5.
dc.identifier.citedreferenceMerad M, Martin JC. Pathological inflammation in patients with COVID‐19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020; 20: 355 ‐ 362.
dc.identifier.citedreferenceManjili RH, Zarei M, Habibi M, Manjili MH. COVID‐19 as an acute inflammatory disease. J Immunol. 2020; 205: 12 ‐ 19.
dc.identifier.citedreferenceNicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003; 361: 1773 ‐ 1778.
dc.identifier.citedreferenceLiao M, Liu Y, Yuan J, et al. Single‐cell landscape of bronchoalveolar immune cells in patients with COVID‐19. Nat Med. 2020; 26: 842 ‐ 844.
dc.identifier.citedreferenceLee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID‐19 and influenza highlights the role of type I interferons in development of severe COVID‐19. Sci Immunol. 2020; 5: eabd1554.
dc.identifier.citedreferenceWen W, Su W, Tang H, et al. Immune cell profiling of COVID‐19 patients in the recovery stage by single‐cell sequencing. Cell Discov. 2020; 6: 31.
dc.identifier.citedreferenceChannappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte‐macrophage responses cause lethal pneumonia in SARS‐CoV‐infected mice. Cell Host Microbe. 2016; 19: 181 ‐ 193.
dc.identifier.citedreferenceChen Y F, Z, Diao B, Wang R, Wang G, Wang C, Tan Y, Liu L, Wang C, Liu Y, Liu Y, Yuan Z, Ren L, Wu Y. The novel severe acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2) directly decimates human spleens and lymph nodes. medRxiv 2020;medRxiv 2020.03.27.20045427. https://doi.org/10.1101/2020.03.27.20045427.
dc.identifier.citedreferenceZiegler CGK, Allon SJ, Nyquist SK, et al. SARS‐CoV‐2 receptor ACE2 Is an interferon‐stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020; 181: 1016 ‐ 1035. e1019.
dc.identifier.citedreferenceDas R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016; 127: 1666 ‐ 1675.
dc.identifier.citedreferenceAlbeituni S, Verbist KC, Tedrick PE, et al. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood. 2019; 134: 147 ‐ 159.
dc.identifier.citedreferenceAhmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open‐label, single‐centre, pilot trial. Lancet Haematol. 2019; 6: e630 ‐ e637.
dc.identifier.citedreferenceDai XM, Ryan GR, Hapel AJ, et al. Targeted disruption of the mouse colony‐stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002; 99: 111 ‐ 120.
dc.identifier.citedreferenceWiktor‐Jedrzejczak W, Bartocci A, Ferrante AW Jr, et al. Total absence of colony‐stimulating factor 1 in the macrophage‐deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A. 1990; 87: 4828 ‐ 4832.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajh25985.pdf
Size:
689.5KB
Format:
PDF
View/Open
Name:
ajh25985_am.pdf
Size:
192.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.